Patents by Inventor Jeffrey R. Spencer
Jeffrey R. Spencer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9657024Abstract: Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.Type: GrantFiled: November 20, 2013Date of Patent: May 23, 2017Assignee: STATegics, Inc.Inventors: Juha Punnonen, Jeffrey R. Spencer, Timothy J. Church, Connie S. Tettenborn, Karen Lariosa-Willingham, Dmitri Leonoudakis, James L. Miller
-
Publication number: 20150307498Abstract: Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.Type: ApplicationFiled: November 20, 2013Publication date: October 29, 2015Inventors: Juha PUNNONEN, Jeffrey R. SPENCER, Timothy J. CHURCH, Connie S. TETTENBORN, Karen Lariosa-Willingham, Dimitri LEONOUDAKIS, James L. MILLER
-
Patent number: 9163027Abstract: Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.Type: GrantFiled: November 20, 2013Date of Patent: October 20, 2015Assignee: STATegics, Inc.Inventors: Juha Punnonen, Jeffrey R. Spencer, Timothy J. Church, Connie S. Tettenborn, Karen Lariosa-Willingham, Dimitri Leonoudakis, James L. Miller
-
Publication number: 20140142122Abstract: Disclosed herein are erythropoietin-mimetic compounds of Formula I, which modulate the survival, function, or differentiation of, for example, kidney cells, neurons, erythroid cells, or other erythropoietin-responsive cells. The present invention also relates to compounds and methods that preferentially modulate cells expressing the tissue-protective erythropoietin receptor. The compounds of the invention are useful in preventing and treating diseases, such as anemia, organ injury, and diseases of the central nervous system, and as an adjunct to cellular treatments, such as stem cell therapies.Type: ApplicationFiled: November 20, 2013Publication date: May 22, 2014Applicant: STATegics, Inc.Inventors: Juha PUNNONEN, Jeffrey R. SPENCER, Timothy J. CHURCH, Connie S. TETTENBORN, Karen LARIOSA-WILLINGHAM, Dimitri LEONOUDAKIS, James L. MILLER
-
Patent number: 8143287Abstract: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.Type: GrantFiled: August 10, 2010Date of Patent: March 27, 2012Assignee: Stategics, Inc.Inventors: Jeffrey R. Spencer, Juha Punnonen
-
Publication number: 20100323965Abstract: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.Type: ApplicationFiled: August 10, 2010Publication date: December 23, 2010Applicant: STATegics, Inc.Inventors: Jeffrey R. SPENCER, Juha Punnonen
-
Patent number: 7786159Abstract: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.Type: GrantFiled: November 30, 2007Date of Patent: August 31, 2010Assignee: Stategics, Inc.Inventors: Jeffrey R. Spencer, Juha Punnonen
-
Publication number: 20080139621Abstract: The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.Type: ApplicationFiled: November 30, 2007Publication date: June 12, 2008Applicant: STATegics, Inc.Inventors: Jeffrey R. Spencer, Juha Punnonen
-
Patent number: 6861419Abstract: The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula I: wherein the dashed lines, A1, A2, A3, X1 and R1 are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of capases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.Type: GrantFiled: April 18, 2001Date of Patent: March 1, 2005Assignee: Cytovia, Inc.Inventors: John A. Drewe, Sui Xiong Cai, Emma Jane Shelton, Joane Litvak, David Sperandio, Jeffrey R. Spencer, Martin Sendzik
-
Publication number: 20030232789Abstract: The present invention provides novel compounds of Formula (I), its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The present invention also provides a process for the selective acylation of an amino group.Type: ApplicationFiled: October 24, 2002Publication date: December 18, 2003Inventors: Darin Arthur Allen, Danny Peter Claude McGee, Jeffrey R Spencer
-
Publication number: 20030212120Abstract: Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.Type: ApplicationFiled: March 14, 2003Publication date: November 13, 2003Applicants: Axys Pharmaceuticals, Inc., ARRIS PHARMACEUTICAL CORPORATION a Delaware CorporationInventors: Timothy J. Church, Neil Scott Cutshall, Anthony R. Gangloff, Thomas E. Jenkins, Martin S. Linsell, Joane Litvak, Kenneth D. Rice, Jeffrey R. Spencer, Vivian R. Wang
-
Patent number: 6562854Abstract: Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.Type: GrantFiled: June 4, 2001Date of Patent: May 13, 2003Assignee: Axys Pharmaceuticals, Inc.Inventors: Timothy J. Church, Neil Scott Cutshall, Anthony R. Gangloff, Thomas E. Jenkins, Martin S. Linsell, Joane Litvak, Kenneth D. Rice, Jeffrey R. Spencer, Vivian R. Wang
-
Publication number: 20020052343Abstract: The present invention provides novel compounds of Formula I: 1Type: ApplicationFiled: December 14, 2000Publication date: May 2, 2002Inventors: Darin Arthur Allen, Danny Peter Claude McGee, Jeffrey R. Spencer
-
Publication number: 20020010169Abstract: The present invention is directed to substituted 1,4-thiazepine and analogs thereof, represented by the general Formula I: 1Type: ApplicationFiled: April 18, 2001Publication date: January 24, 2002Applicant: Cytovia, Inc.Inventors: John A. Drewe, Sui Xiong Cai, Emma Jane Shelton, Joane Litvak, David Sperandio, Jeffrey R. Spencer
-
Publication number: 20010053779Abstract: Novel compounds, compositions and methods effective for the prevention and treatment of mast-cell mediated inflammatory disorders are described. The compounds, compositions and methods are effective for the prevention and treatment of inflammatory diseases associated with the respiratory tract, such as asthma and allergic rhinitis, as well as other types of immunomediated inflammatory disorders, such as rheumatoid arthritis, conjunctivitis and inflammatory bowel disease, various dermatological conditions, as well as certain viral conditions. The compounds comprise potent and selective inhibitors of the mast cell protease tryptase. The compositions for treating these conditions include oral, inhalant, topical and parenteral preparations as well as devices comprising such preparations.Type: ApplicationFiled: June 4, 2001Publication date: December 20, 2001Inventors: Timothy J. Church, Neil Scott Cutshall, Anthony R. Gangloff, Thomas E. Jenkins, Martin S. Linsell, Joane Litvak, Kenneth D. Rice, Jeffrey R. Spencer, Vivian R. Wang
-
Patent number: 5994502Abstract: The present invention provides novel inhibitors of oligosaccharyl transferase, methods for producing Glc.sub.3 Man.sub.9 (GlcNAc).sub.2 --P--P--Dol, and methods for producing glycopeptides.Type: GrantFiled: August 19, 1997Date of Patent: November 30, 1999Inventors: Barbara Imperiali, Jeffrey R. Spencer, Tamara L. Hendrickson
-
Patent number: 5721338Abstract: The present invention provides novel inhibitors of oligosaccharyl transferase, methods for producing Glc.sub.3 Man.sub.9 (GlcNAc).sub.2 -P-P-Dol, and methods for producing glycopeptides.Type: GrantFiled: December 7, 1995Date of Patent: February 24, 1998Assignee: California Institute of TechnologyInventors: Barbara Imperiali, Jeffrey R. Spencer, Tamara L. Hendrickson